Expanding JAK Inhibitors to Novel Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of JAK inhibitors to address unmet needs in diverse industries, including aquaculture, livestock, plant health, human exercise performance, and environmental pollution control.
Background and Problem Solved
The original patent focused on treating diseases of the gastrointestinal tract with JAK inhibitors. However, the potential of JAK inhibitors extends beyond this scope. The new inventive concept addresses the limitations of the original patent by exploring novel applications and use cases for JAK inhibitors, thereby unlocking new opportunities for improving health, productivity, and environmental sustainability.
Detailed Description of the Inventive Concept
The new inventive concept involves the use of ingestible devices configured to detect specific targets (e.g., waterborne pathogens, stress in livestock, plant pathogens, muscle fatigue, or environmental pollutants) and release JAK inhibitors to mitigate their effects. This approach enables targeted and controlled delivery of JAK inhibitors, reducing systemic exposure and potential side effects. The ingestible devices can be designed for various formats, such as capsules, tablets, or implants, depending on the specific application and target species.
Novelty and Inventive Step
The new claims introduce a paradigm shift in the use of JAK inhibitors, moving beyond gastrointestinal tract diseases to address unmet needs in distinct industries. The inventive concept's novelty lies in the combination of ingestible devices and JAK inhibitors, which enables targeted delivery and opens up new avenues for improving health, productivity, and environmental sustainability.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different types of JAK inhibitors, varying release mechanisms, or incorporating additional therapeutic agents. Variations may also involve adapting the ingestible devices for specific species, such as companion animals or fish, or developing implantable devices for long-term release of JAK inhibitors.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential across multiple industries, including aquaculture, livestock, plant health, human exercise performance, and environmental pollution control. The market opportunities are vast, with potential applications in improving food production, reducing environmental pollutants, and enhancing human health and well-being.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/0009 |
| A | A61 | A61K9/0004 |
| A | A61 | A61K9/0053 |
| A | A61 | A61K31/519 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical drug delivery systems, with expertise in targeted drug release, JAK inhibitor formulations, and ingestible medical devices for controlled therapeutic interventions
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced training in pharmaceutical engineering, biotechnology, or biomedical engineering, possessing knowledge of drug delivery mechanisms, device design, and therapeutic targeting strategies
Obviousness Rationale
A PHOSITA would recognize that the source patent's core teachings of JAK inhibitor delivery can be readily extended to alternative therapeutic and monitoring applications by leveraging known ingestible device technologies. The fundamental principles of targeted drug release and localized therapeutic intervention demonstrated in the source patent provide a clear technological foundation for exploring novel application domains. The PTD's variations represent predictable engineering adaptations that would be obvious to a skilled practitioner seeking to expand the utility of JAK inhibitor delivery systems.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,669 |
|---|---|
| Title | Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices |
| Assignee(s) | Biora Therapeutics, Inc. |